These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338 [TBL] [Abstract][Full Text] [Related]
5. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658 [TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Lennernäs H; Fager G Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain. Plans-Rubió P Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391 [TBL] [Abstract][Full Text] [Related]
8. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Rader DJ; Davidson MH; Caplan RJ; Pears JS Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of simvastatin for high-risk hypercholesterolemia. Mölgaard J; Wärjerstam-Elf S; Olsson AG Am J Cardiol; 1999 Apr; 83(7):1043-8. PubMed ID: 10190517 [TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies. Davignon J; Hanefeld M; Nakaya N; Hunninghake DB; Insull W; Ose L Am J Cardiol; 1998 Aug; 82(4B):32J-39J. PubMed ID: 9737644 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy. Hunninghake DB Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501 [TBL] [Abstract][Full Text] [Related]
12. Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E. Wang YX; Martin-McNulty B; Huw LY; da Cunha V; Post J; Hinchman J; Vergona R; Sullivan ME; Dole W; Kauser K Atherosclerosis; 2002 May; 162(1):23-31. PubMed ID: 11947894 [TBL] [Abstract][Full Text] [Related]
13. Results of recent large cholesterol-lowering trials and implications for clinical management. Gotto AM Am J Cardiol; 1997 Jun; 79(12):1663-6. PubMed ID: 9202359 [TBL] [Abstract][Full Text] [Related]
14. [On the current debate on lowering LDL cholesterol with ezetimibe]. Breuer HW Dtsch Med Wochenschr; 2010 Nov; 135(44):2201; author reply 2202. PubMed ID: 20979008 [No Abstract] [Full Text] [Related]
15. Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial. Eriksson M; Budinski D; Hounslow N Adv Ther; 2011 Sep; 28(9):811-23. PubMed ID: 21874538 [TBL] [Abstract][Full Text] [Related]
17. LDL-Cholesterol is the King. Goumas GS Angiology; 2009; 60(3):387-8. PubMed ID: 19497926 [No Abstract] [Full Text] [Related]
18. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Heart Protection Study Collaborative Group Lancet; 2011 Dec; 378(9808):2013-2020. PubMed ID: 22115874 [TBL] [Abstract][Full Text] [Related]
19. Effect of HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors on the concentration of insulin-like growth factor-1 (IGF-1) in hypercholesterolemic patients. Szkodziński J; Romanowski W; Hudzik B; Kaszuba A; Nowakowska-Zajdel E; Szkilnik R; Pietrasińska B; Zubelewicz-Szkodzińska B Pharmacol Rep; 2009; 61(4):654-64. PubMed ID: 19815947 [TBL] [Abstract][Full Text] [Related]
20. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis. Ose L; Shah A; Davies MJ; Rotonda J; Maccubbin D; Tribble D; Veltri E; Mitchel Y Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]